Compounds > gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate
Page last updated: 2024-09-03

gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Prostatic Diseases

gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate has been researched along with Prostatic Diseases in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gevenois, PA; Salmon, I; Simon, J; Sintzoff, SA; Stallenberg, B; Struyven, J; Van Regemorter, G1

Trials

1 trial(s) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Prostatic Diseases

ArticleYear
Gadolinium-DOTA enhanced MR imaging of prostatic lesions. Preliminary results on 14 cases.
    Journal belge de radiologie, 1992, Volume: 75, Issue:1

    Topics: Contrast Media; Gadolinium; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Male; Organometallic Compounds; Prostatic Diseases; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis

1992